Zentalis Pharmaceuticals (ZNTL) Q1 2026 earnings summary

Executive summary

• Advanced azenosertib in late-stage clinical development for Cyclin E1-positive platinum-resistant ovarian cancer (PROC), with pivotal dose (400mg QD 5:2) selected and ongoing pivotal trials and companion diagnostic development.

• Initiated ASPENOVA Phase 3 confirmatory trial and expanded DENALI Phase 2 to include new patient cohorts, aiming for accelerated and full approvals.

• No products approved or revenue from product sales; operations funded by equity offerings and collaborations.

• Net loss for Q1 2026 was $35.4 million, improved from $48.3 million in Q1 2025, reflecting lower operating expenses post-restructuring.

• Cash, cash equivalents, and marketable securities totaled $211.8 million as of March 31, 2026, expected to fund operations into late 2027.

Financial highlights

• Q1 2026 net loss: $35.4 million, or $0.50 per share, compared to $48.3 million, or $0.67 per share, in Q1 2025.

• Research and development expenses increased to $28.7 million (from $27.2 million), driven by clinical and manufacturing costs for DENALI and ASPENOVA trials.

• General and administrative expenses decreased to $9.1 million (from $10.6 million), mainly due to lower personnel costs.

• No restructuring expenses in Q1 2026 (compared to $7.8 million in Q1 2025 following a 40% workforce reduction).

• Cash, cash equivalents, and marketable securities were $211.8 million as of March 31, 2026, down from $245.9 million at December 31, 2025.

Outlook and guidance

• DENALI Phase 2 topline readout expected by year-end 2026, with potential to support accelerated approval, pending data and FDA feedback.

• ASPENOVA Phase 3 trial is enrolling and designed to support conversion to full approval and ex-US registrations.

• Cash runway projected into late 2027, supporting execution of key clinical milestones; additional capital will be needed for full development and commercialization.

• Focus remains on advancing azenosertib in PROC and exploring broader franchise potential in other tumor types.